Treatment Information

Back

Kidney (Renal) Cancer treatment details. Immunotherapy.

Aarhus University Hospital, Aarhus, Denmark.

Survival: monthsCountry:Denmark
Toxiciy Grade:4City/State/Province:Aarhus
Treatments:ImmunotherapyHospital:Aarhus University Hospital
Drugs:Journal:Link
Date:Mar 2002

Description:

Patients: This Phase II study involved 46 patients with metastatic renal cell carcinoma, 34 men and 12 women. The median age was 57. Prior therapies included nephrectomy (27 patients), radiation therapy (2 patients) and hormone therapy (2 patients). Sixteen patients had not received any prior therapy.

Treatment: The treatment consisted of the drug, histamine dihydrochloride in combination with immunotherapy - interleukin-2 and interferon-alpha.

Toxicity: There was one grade 4 toxicity (thrombocytopenia with bleeding). Grade 3 toxicities included fatigue/malaise, nausea, stomatitis, and neutropenia.

Results: Median survival was 16.3 months.

Support: The study was supported by Maxim Pharmaceuticals. This company markets histamine dihydrochloride.

Correspondence: Dr. F. Donskov





Back